Wednesday, June 10, 2026

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8377444

    Therapeutic agent or preventive agent for osteoarthritis

    AXIS · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 8377926

    Aminopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8377945

    Small molecule inhibitors of spleen tyrosine kinase (SYK)

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 8378124

    Preparation of protected alpha-keto beta-amino esters and amides

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 8377872

    Cyclic P3 tripeptide hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8378121

    Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8378107

    Heteroaryl antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8377966

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8377637

    MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8378109

    Labeled ALPHA4BETA2 ligands and methods therefor

    The Regents of the University of California · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8377924

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 8377965

    Crystalline forms of a biphenyl compound

    Theravance, Inc. · Granted Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 8383388

    Modified coagulation factor IX polypeptides and use thereof for treatment

    Catalyst Biosciences, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 8383576

    LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 8383669

    Crystalline form of a 3-phenoxymethylpyrrolidine compound

    Theravance, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 8383093

    Subcutaneous delivery of poly(oxazoline) conjugates

    Serina Therapeutics, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 8383102

    Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8383360

    Methods of diagnosing and treating autism

    The Regents of the University of California · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 8383589

    Aegyptin and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8383132

    Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

    The Regents of the University of California · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. US 8383380

    Segmented polymers and their conjugates

    Nektar Therapeutics · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. US 8383580

    Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. US 8383628

    Pyridyl derivatives and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. US 8383633

    Aminopyrimidines useful as kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. US 8383647

    Quinoline derivative

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  26. US 8383858

    Processes and intermediates for preparing steric compounds

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  27. US 8383665

    Immunomodulatory compositions

    Summit (Wales) Limited · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  28. US 8383785

    Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  29. US 8383805

    RNAi modulation of SCAP and therapeutic uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  30. US 8383817

    Benztropine compounds and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  31. US 8383654

    Heterocyclic antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  32. US 8383645

    Stable laquinimod preparations

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  33. US 8383583

    Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  34. US 8383113

    Anti-ADDL antibodies and uses thereof

    Northwestern University · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  35. US 8383099

    Adoptive cell therapy with young T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  36. US 8383133

    Conjugates of Plasmodium falciparum surface proteins as malaria vaccines

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  37. US 8388969

    Interleukin-1 alpha antibodies and methods of use

    XBIOTECH INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  38. US 8388643

    Bioabsorbable polymeric implants and a method of using the same to create occlusions

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  39. US 8389734

    Amides useful as inhibitors of voltage-gated sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  40. US 8388930

    Diagnosis and assessment of skeletal related disease using calcium 41

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  41. US 8388956

    Interleukin-1 alpha antibodies and methods of use

    XBIOTECH INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  42. US 8389557

    Triazole derivatives useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  43. US 8388963

    Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  44. US 8388933

    Multimeric protein toxins to target cells having multiple identifying characteristics

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  45. US 8389232

    Fluorescence detection of poison oak oil

    The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  46. US 8389495

    Olioodeoxynucleotide and its use to induce an immune response

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  47. US 8389228

    Process for the measurement of the potency of glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  48. US 8389231

    Assays, method and compositions that exploit a mycobacterial iron acquistion pathway in cells

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.